Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) (TA965)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2024
Roflumilast for treating chronic obstructive pulmonary disease (TA461)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 July 2017
Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease [ID1237]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC